The metabolic effects of lopinavir/ritonavir in HIV-negative men

AIDS

Volumn 18, Issue 4, 2004, Pages 641-649

  Lee, Grace A ^a,b   Seneviratne, Tara ^a,b   Noor, Mustafa A ^a,b   Lo, Joan C ^b,c   Schwarz, Jean Marc ^b,c,d   Aweeka, Francesca T ^e   Mulligan, Kathleen ^b,c   Schambelan, Morris ^b,c   Grunfeld, Carl ^a,b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Body composition; Cholesterol; HIV; HIV protease inhibitors; Insulin resistance; Lipodystrophy; Ritonavir; Triglycerides

Indexed keywords

FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN A; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY FAT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRY SKIN; DUAL ENERGY X RAY ABSORPTIOMETRY; ENERGY EXPENDITURE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; LIPODYSTROPHY; MALE; NAUSEA; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; XEROSTOMIA;

ADULT; AGED; BLOOD GLUCOSE; BODY COMPOSITION; CHOLESTEROL, VLDL; DRUG COMBINATIONS; FATTY ACIDS, NONESTERIFIED; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HIV PROTEASE INHIBITORS; HIV SERONEGATIVITY; HUMANS; INSULIN; LIPIDS; MALE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR; TRIGLYCERIDES;

EID: 1642315800     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200403050-00008     Document Type: Article

References (33)

1. Sullivan AK, Feher MD, Nelson MR, Gazzard BG. Marked hypertriglyceridaemia associated with ritonavir therapy [Letter]. AIDS 1998, 12:1393-1394.
2. Dube MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor- associated hyperglycaemia. Lancet 1997, 350:713-714.
3. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquired Immune Defic Syndr 2000, 23:35-43.
4. Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother 1999, 33:859-863.
5. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999, 100:700-705.
6. Roge BT, Katzenstein TL, Gerstoft J. Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir. Scand J Infect Dis 2001, 33:306-311.
7. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001, 15:F11-F18.
8. Yarasheski KE, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquired Immune Defic Syndr 1999, 21:209-216.
9. Walli R, Herfort O, Michl GM, Demant T, Jèager H, Dieterle C, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998, 12:F167-F173.
10. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000, 14:37-49.
11. Saves M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002, 34:1396-1405.
12. Shumak SL. Increased insulin sensitivity and increased rates of insulin clearance in men with human immunodeficiency virus (HIV) infection. Metabolism 1992, 41:682.
13. Hommes MJ, Romijn JA, Endert E, Eeftinck Schattenkerk JK, Sauerwein HP. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism: Clin Exp 1991, 40:651-656.
14. Sadler BM, Piliero PJ, Preston SL, Lloyd PP, Lou Y, Stein DS. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS 2001, 15:1009-1018.
15. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000, 14:51-57.
16. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000, 275:20251-20254.
17. Hruz PW, Murata H, Qiu H, Mueckler M. Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 2002, 51:937-942.
18. Schwarz JM, Neese RA, Turner S, Dare D, Hellerstein MK. Short-term alterations in carbohydrate energy intake in humans. Striking effects on hepatic glucose production, de novo lipogenesis, lipolysis, and whole-body fuel selection. J Clin Invest 1995, 96:2735-2743.
19. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:E214-E223.
20. World Health Organization. Diabetes mellitus: report of a WHO study group. Technical Report Series. World Health Organization; 1985.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
22. Lo JC, Mulligan K, Noor MA, Schwarz JM, Halvorsen RA, Grunfeld C, Schambelan M. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 2001, 86:3480-3487.
23. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998, 351:867-870.
24. Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ritonavir). Ann Pharmacother 2002, 36:1193-1203.
25. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsberg HN, Sturley SL. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001, 7:1327-1331.
26. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001, 276:37514-37519.
27. Segerer S, Bogner JR, Walli R, Loch O, Goebel FD. Hyperlipidemia under treatment with proteinase inhibitors. Infection 1999, 27:77-81.
28. Berthold HK, Parhofer KHC, Ritter MM, Addo M, Wasmuth JC, Schliefer K, et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med 1999, 246:567-575.
29. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001, 15:2407-2414.
30. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquired Immune Defic Syndr 2003, 32:18-29.
31. Dube MP, Qian D, Edmondson-Melancon H, Sattler FR, Goodwin D, Martinez C, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002, 35:475-481.
32. Woerle H, Mariuz R, Meyer C, Reichman R, Popa E, Dostou J, et al. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 2003, 52:918-925.
33. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002, 346: 2039-2046.